Jing‐Quan Wang - Concepedia

Author

Jing‐Quan Wang

St. John's University ORCID

Also Known As

J Q Wang, Jing-Quan Wang, Jing-quan Wang, Jingquan Wang, Jing‐Quan Wang, Wang Jingquan, Wang, Jingquan, Yi-Nan Liu

146

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

St. John's University Guangzhou Medical University Weifang Medical University Sun Yat-sen University The Seventh Affiliated Hospital of Sun Yat-sen University

About

Jing‐Quan Wang is an author at St. John's University specializing in medicine, drug resistance, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	927
2	Health Sciences	4	4	169
3	Natural Sciences	4	4	136
4	Engineering	1	1	18
5	Public Health	1	1	52

Jing‐Quan Wang

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells Ning Ji, Yuqi Yang, Chao‐Yun Cai, Cancer Letters Abcg2-overexpressing Cancer CellsOncologyMedicineMultidrug ResistanceCancer Biology	2018	105
VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters Ning Ji, Yuqi Yang, Chao‐Yun Cai, Frontiers in Pharmacology Abc TransportersAtpase AnalysisCancer BiologyTumor BiologyDrug Resistance	2018	72
Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance Bo Wang, Liying Ma, Jing‐Quan Wang, Journal of Medicinal Chemistry Pharmaceutical ScienceP-glycoprotein-mediated Mutidrug ResistancePharmacotherapyDrug ResistanceMedicinal Chemistry	2018	70
Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells Zhuo‐Xun Wu, Qiu‐Xu Teng, Chao‐Yun Cai, Biochemical Pharmacology Tumor BiologyMedicinePharmacologyImmune Checkpoint InhibitorAnti-cancer Agent	2019	68
Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance Ning Ji, Yuqi Yang, Zi‐Ning Lei, Biochemical Pharmacology Molecular PharmacologyMedicinal ChemistryMedicinePharmacotherapyAntimicrobial Chemotherapy	2018	66
Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression Dan Liao, Wei Zhang, Pranav Gupta, Molecules	2019	63
Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells Wei Zhang, Yingfang Fan, Chao‐Yun Cai, Frontiers in Pharmacology	2018	56
Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19 Weixi Shen, Rongcheng Luo, Jing‐Quan Wang, Frontiers in Public Health Virus EpidemiologyViral DiagnosticsImmunodeficienciesImmunologyViral Pathogenesis	2021	52
Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells Jing‐Quan Wang, Jonathan Y. Li, Qiu‐Xu Teng, Cancers Bcl-2 InhibitorImmunologyImmunotherapeuticsDrug ResistanceOncology	2020	51
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells Weiguo Feng, Meng Zhang, Zhuo‐Xun Wu, Frontiers in Oncology Tumor BiologyOncologyHealth SciencesAbcb1 Atpase ActivityMedicine	2020	48

Page 1